What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment

Tumor-infiltrating lymphocyte (TIL) is an emerging therapy that may one day change the approach to the management of solid tumors including melanoma, NSCLC, and more. Join us for a conversation with Dr. Omid Hamid, one of the principal investigators pioneering TIL therapy in clinical trials, as we discuss this novel treatment method. Dr. Hamid will break down what the community physician needs to know about this emerging therapy as it makes it’s way out of clinical trials and into the clinic. 

Featuring:
Omid Hamid, MD
Cedars-Sinai CANCER
Los Angeles, CA